A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

NCT01672775 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell
Renal Cell Carcinoma of Papillary Histology
Renal Cell Carcinoma With Clear Cell Histology
Renal Cell Carcinoma With Non-Clear Cell Histology

Interventions

DRUG: AGS-16C3F

Sponsor

Agensys, Inc.